Horizon Europe et Canada : Bridging the Atlantic – Health 2025

Le Service des délégués commerciaux (SDC) du Canada organise, en collaboration avec EIT Health et les PCN Santé de France, du Royaume-Uni et de l’Irlande, un événement de réseautage dédié aux appels Horizon Europe du Cluster Santé :

  • Quoi ? « Horizon Europe et Canada : Bridging the Atlantic – Health 2025 »
  • Quand ? Jeudi 27 mars 2025
  • Heure ? 16 h à 18 h (Bruxelles/CET)

👉 Cliquez sur REGISTER pour participer.

POUR PLUS D’INFORMATIONS, CLIQUEZ SUR LE LIEN D’INSCRIPTION

 Thématiques du réseautage :

 ROOM 1 CARE

  • HORIZON-HLTH-2025-03-STAYHLTH-01-two-stage: Improving the quality of life of persons with intellectual disabilities and their families
  • HORIZON-HLTH-2025-01-CARE-01: End user-driven application of Generative Artificial Intelligence models in healthcare (GenAI4EU)

ROOM 2 DISEASE

  • HORIZON-HLTH-2025-01-DISEASE-03: Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential
  • HORIZON-HLTH-2025-01-DISEASE-06: Implementation research addressing strategies to strengthen health systems for equitable high-quality care and health outcomes in the context of non-communicable diseases
  • HORIZON-HLTH-2025-01-DISEASE-01: Testing safety and efficacy of phage therapy for the treatment of antibiotic-resistant bacterial infections

ROOM 3 TOOLS

  • HORIZON-HLTH-2025-01-TOOL-03: Leveraging multimodal data to advance Generative Artificial Intelligence applicability in biomedical research (GenAI4EU)
  • HORIZON-HLTH-2025-01-TOOL-05: Boosting the translation of biotech research into innovative health therapies
  • HORIZON-HLTH-2025-01-IND-01: Optimising the manufacturing of Advanced Therapy Medicinal Products (ATMPs)

ROOM 4 CANCER

  • CANCER TOPIC A: Examining the link between environmental exposure, pediatric cancer onset and health outcomes
  • CANCER TOPIC B: Surgical interventions for locally advanced or metastatic disease
  • CANCER TOPIC C: Clinical trials for targeted cancer therapeutics